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Abstract
Background: Histiocytic malignancies in both humans and dogs are rare and poorly understood. While canine
histiocytic sarcoma (HS) is uncommon in the general domestic dog population, there is a strikingly high incidence
in a subset of breeds, suggesting heritable predisposition. Molecular cytogenetic profiling of canine HS in these
breeds would serve to reveal recurrent DNA copy number aberrations (CNAs) that are breed and/or tumor
associated, as well as defining those shared with human HS. This process would identify evolutionarily conserved
cytogenetic changes to highlight regions of particular importance to HS biology.
Methods: Using genome wide array comparative genomic hybridization we assessed CNAs in 104 spontaneously
occurring HS from two breeds of dog exhibiting a particularly elevated incidence of this tumor, the Bernese
Mountain Dog and Flat-Coated Retriever. Recurrent CNAs were evaluated further by multicolor fluorescence in situ
hybridization and loss of heterozygosity analyses. Statistical analyses were performed to identify CNAs associated
with tumor location and breed.
Results: Almost all recurrent CNAs identified in this study were shared between the two breeds, suggesting that
they are associated more with the cancer phenotype than with breed. A subset of recurrent genomic imbalances
suggested involvement of known cancer associated genes in HS pathogenesis, including deletions of the tumor
suppressor genes CDKN2A/B, RB1 and PTEN. A small number of aberrations were unique to each breed, implying
that they may contribute to the major differences in tumor location evident in these two breeds. The most highly
recurrent canine CNAs revealed in this study are evolutionarily conserved with those reported in human histiocytic
proliferations, suggesting that human and dog HS share a conserved pathogenesis.
Conclusions: The breed associated clinical features and DNA copy number aberrations exhibited by canine HS
offer a valuable model for the human counterpart, providing additional evidence towards elucidation of the
pathophysiological and genetic mechanisms associated with histiocytic malignancies. Extrapolation of data derived
from canine histiocytic disorders to human histiocytic proliferation may help to further our understanding of the
propagation and cancerization of histiocytic cells, contributing to development of new and effective therapeutic
modalities for both species.
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Background
Histiocytic malignancies in human patients are rare but
aggressive cancers associated with high mortality [1-4].
Pathologic and cytogenetic data for these malignancies
are sparse, based on a few early case studies e.g.[5-7]
and a single larger study of 18 histiocytic sarcomas (HS)
[2]. On a molecular level, deletions of CDKN2A/
p14ARF, TP53, MDM2 and PTEN have been reported in
human histiocytic disorders [4,8-14], but their etiology
remains poorly understood. The clinical behavior of
these diseases is also unclear, and the optimal course of
treatment remains a matter of debate [4,15]. Elucidation
of the genetic basis of many human cancers has been
aided by identification of recurrent genomic DNA copy
number aberrations (CNAs) affecting dosage of target
genes involved in cancer pathogenesis. The diagnostic,
prognostic and therapeutic significance of numerous
CNAs in a variety of common cancers is well described
[16]. However, for rare cancers, including HS, the lim-
itations on sample availability preclude the generation of
comprehensive data regarding recurrent CNAs.
Histiocytic cancers are uncommon within the domestic
dog population in general, but there is a highly elevated
incidence in several breeds, including the Bernese Moun-
tain Dog (BMD) and Flat-Coated Retriever (FCR), suggest-
ing heritable risk factors and indicating that these breeds
may share genetic characteristics contributing to tumor
initiation and progression [17-22]. Canine HS are histolo-
gically comparable to the corresponding human cancers,
involving proliferation of members of both histiocytic
lineages (dendritic cells (DC) and macrophages) with
which they share pathologic features [17,18]. With only
small numbers of available human samples, we propose
that the canine model provides a unique opportunity to
identify recurrent genomic lesions associated with sponta-
neous HS, and provide greater insight into the pathogen-
esis and genetic etiology in human patients.
For this study we hypothesized that recurrent CNAs
exist in canine HS, detection of which would identify
regions of the canine genome containing genes associated
with HS initiation and progression. Approximately ~25%
of all tumors diagnosed in the BMD are reported to be
HS, and a recent study estimated that 80% of canine dis-
seminated HS cases are diagnosed in the BMD, sugges-
tive of a multigenic or multifactorial mode of
transmission [22,23]. The typical age of onset in the
BMD is 6.5 years, with 82% and 55% of cases involving
an internal organ and multiple organs, respectively
[22,23]. This latter presentation represents the dissemi-
nated form of the disease, often referred to as malignant
histiocytosis. Tumor progression is rapid with a mean
survival time following diagnosis of only 49 days [23].
With such an aggressive behavior and high prevalence in
the breed, HS has a huge impact on BMD longevity. HS
also is the most common malignant tumor identified in
the FCR, accounting for at least 40% of all tumors diag-
nosed in this breed, with an average age of onset of 8.5
years [24,25]. Tumors in the FCR are generally located in
the muscle region surrounding a joint, with a high rate of
metastasis to local lymph nodes, spleen, thorax and
abdominal organs. While treatments are available for pal-
liation of clinical signs and extension of life, this tumor
carries a poor prognosis in the FCR, with a reported
median survival of only four months [25].
We evaluated genome-wide CNAs in a cohort of histo-
logically confirmed canine HS cases using array compara-
tive genomic hybridization (aCGH), supplemented with
fluorescence in situ hybridization (FISH) and loss of het-
erozygosity (LOH) analysis. We identified recurrent CNAs
common to HS in both breeds (BMD and FCR), indicating
an association with tumor phenotype. These changes
included genomic imbalances encompassing well defined
cancer associated genes (CDKN2A/B, RB1, PTEN). Epide-
miological data revealed a significant difference in the ana-
tomical location of histiocytic tumors between the two
breeds. A subset of CNAs was also associated significantly
with breed. These data suggest that at least some of the
CNAs are associated with breed and/or tumor location,
rather than tumor phenotype.
Having defined aberrant genomic regions in two
breeds of dog with a high incidence of HS, subsequent
comparative molecular analysis of such regions, both in
dog and human patients, will provide opportunities to
gain greater insight into our understanding of the path-
ways implicated in histiocytic cancers, providing a first
step on the road to developing new treatments.
Methods
Case recruitment and histological evaluation of canine
histiocytic tumors
No animal experimentation was performed during this
study. All patients evaluated in this study were from
family owned dogs with a confirmed histiocytic malig-
nancy. All blood and tumor samples were taken with
informed owner consent by veterinarians between 2003-
2008. One hundred and forty six patients were recruited
for this study. Unfixed tumor biopsies were submitted
from 125 cases that had not previously received treat-
ment for their HS other than for palliative care. Tumor
biopsies were obtained under sterile conditions, either as
part of a routine diagnostic biopsy procedure, during sur-
gery, or immediately following euthanasia. All FCR cases
(n = 45) originated from the USA, while the BMD cases
(n = 101) were derived from the USA (n = 68 patients) or
France (n = 33 patients). The anatomical location of
tumors evident at the time of diagnosis and/or necropsy
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was recorded for each case in one of five categories:
tumor present in i) one internal organ; ii) multiple inter-
nal organs (equivalent to disseminated HS); iii) lymph
node only; iv) limb only; v) skin only. The last two loca-
tions were regarded as localized HS. A representative
portion of the tumor was fixed in 10% neutral-buffered
formalin. Histological specimens were evaluated by
board-certified veterinary pathologists (JC, JA) using rou-
tine hematoxylin-eosin (H&E) staining and antibodies
against CD3 (T-cell marker), CD18 (hematopoietic
marker), CD79a (B-cell marker), MHC class II, E-cad-
herin and Thy-1. In rare cases where the pathology
remained inconclusive (and where frozen tissue was
available) tissues were evaluated further with CD11c and
CD11d. In such cases, a diagnosis of HS was confirmed
when tumor cells were positive for CD11c or CD11d
markers and negative for CD3 and CD79a markers.
Tumors were classified according to the criteria of Affol-
ter and Moore (2002)[17].
Array comparative genomic hybridization (aCGH) analysis
Genomic DNA was isolated from representative speci-
mens of unfixed tumor tissue. aCGH analysis was per-
formed as described previously [26] using a custom
genomic microarray comprising canine bacterial artificial
chromosome (BAC) clones distributed at ~1 Mb inter-
vals within the 7.6× canine genome sequence assembly
[27]. All BAC clones had been previously verified to
map to a unique chromosomal location by multicolor
fluorescence in situ hybridization (FISH) analysis [26].
Equimolar quantities of blood-derived DNA isolated
from five or more unrelated, cancer free individuals
were used as breed matched reference samples. Data
analysis was performed as described elsewhere [26,28].
Tumor-associated genomic imbalances were detected
using the aCGH-Smooth algorithm [29] with threshold
limits for detection of CNAs set at log2 ratio values of
tumor DNA vs. reference DNA equivalent to 1.15:1
(copy number gain) and 0.85:1 (copy number loss).
CNAs were defined as recurrent or highly recurrent
when common to ≥30% and ≥50% of cases, respectively.
The megabase (Mb) location of dog genes along the cor-
responding chromosome were based on the canFam v2
genome sequence assembly [27] accessed via the UCSC
genome browser http://genome.ucsc.edu/.
Loss of heterozygosity (LOH) analysis
Genomic regions exhibiting recurrent DNA copy num-
ber loss in HS were further evaluated for LOH using the
M13-tailed primer method [30]. PCR primers flanking
microsatellite sequences [31] located within these
regions are listed in Additional file 1: Table S1. Each
locus was amplified independently from paired tumor-
and blood-derived DNA from each patient evaluated.
PCR was conducted in 10 μl reactions containing 0.8
units Taq polymerase (Go Taq, Promega), 1.0 μl 10×
reaction buffer (Promega), 0.25 mM each dNTP,
0.15 μM each microsatellite-specific primer, 0.1 μM 5’
fluorescently labeled M13 primer and 50 ng template
DNA. The M13 primer was tagged at the 5’ end either
with PET, VIC, FAM or NED (Applied Biosystems) to
facilitate multiplexing of products. Amplification condi-
tions were as follows: 95°C for 2 min followed by 35
cycles of 94°C for 30 s, 58°C for 30 s and 72°C for 30 s,
followed by a 2-min final extension at 72°C. Amplicons
were visualized and evaluated by capillary-electrophor-
esis (3730xl DNA Analyzer, Applied BioSystems). Two
parameters were calculated for each sample: the allelic
ratio (AR) and allelic balance (AI). The AR was calcu-
lated by AR = (peak area 1)/(peak area 2); AI by AI =
AR (tumor)/AR (blood). When AI ≥ 1.5 or ≤ 0.67, the
region was considered to be deleted.
Cytogenetic and fluorescence in situ hybridization (FISH)
analysis
Where viable tumor tissue was available, interphase
nuclei and chromosome preparations were generated for
FISH analysis. Primary tumor specimens were disaggre-
gated using Collagenase B (Roche) and the resulting cell
suspensions harvested directly, or from low passage
(n <2) primary cell cultures, using conventional techni-
ques of colcemid arrest, hypotonic treatment and
methanol/glacial acetic acid fixation, as described else-
where [32]. Multicolor FISH analysis was carried out as
described previously [33] using BAC clones representing
regions of the genome highlighted by aCGH analysis.
All probes were hybridized first onto metaphase chro-
mosome preparations from a pool of clinically healthy
dogs to confirm the expected copy number for each
probe at the expected chromosomal location. Image
data were assessed from a minimum of 30 representative
cells from each control/case evaluated.
Statistical analysis
aCGH, clinical and demographic data were compared
with Mann-Whitney U tests in the case of continuous
outcome variables, and with Fisher’s Exact tests in the
case of categorical outcomes. These methods are non-
parametric, requiring no distributional assumptions to
retain validity. Principal components analysis (PCA) is
well-established in human genetics to detect geographic
and racial background differences in human populations
[34,35]. PCA was performed to evaluate potential popu-
lation substructure in the USA and French BMD popu-
lations, and to test for differences in CNA frequency
between the two breeds [36-38]. Association analyses
were performed with Fisher’s Exact tests to test for asso-
ciation between aberration frequencies and breed. To
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control family-wise error rates and correct for multiple
comparisons, permutation testing was performed, deriv-
ing empirically p-value cut-offs of significance corre-
sponding to a family-wise error rate of 0.05 [39].
Statistical analyses were performed using JMP Genomics
v4 and SAS 9.1.3 (SAS Institute, Cary, NC) and Stata
v.11 http://www.stata.com.
Results
Statistical evaluation of epidemiological data
Evaluation of the 113 HS cases recruited from within
the USA provided an opportunity for direct comparison
of their epidemiological characteristics. The USA cohort
comprised 68 BMD (33 male, 35 female) and 45 FCR
(20 male, 25 female), all of whom were registered with
the American Kennel Club. The mean age at diagnosis
was 8.6 years ± 1.7 for the FCR (range 5 to 12 years)
and 7.7 years ± 1.9 for the BMD (range 2 to 12 years),
which also showed a secondary peak at 10 years of age
(Figure 1). These data indicate that within the US
patients the age of onset of HS was significantly higher
in the FCR than the BMD (p = 0.01, Mann-Whitney U
test).
The anatomical location of the tumor(s) also showed
significant variation between the two breeds (Figure 2),
with 87% of BMDs presenting with HS affecting one or
more internal organs compared with 48% of FCRs (p <
0.001, Fisher’s Exact test). Moreover, occurrence of HS
on a limb was >10 times more frequent in the FCR than
in the BMD (38.4% versus 3.2%). With the assumption
that isolated skin and limb tumors correspond to loca-
lized HS, we may surmise that the prevalence of loca-
lized HS is seven times more frequent in the FCR than
in the BMD (46.1% versus 6.5%) and that of dissemi-
nated HS is approximately two fold higher in the BMD
than the FCR (50.8% versus 25.6%).
Overview of DNA copy number aberrations revealed by
aCGH
Metaphase preparations were generated from >20 HS
tumor biopsies from both BMD and FCR. The domestic
dog karyotype comprises 38 pairs of single-armed chro-
mosomes and a pair of bi-armed sex chromosomes
(2n = 78). Conventional cytogenetic evaluation of HS
cases revealed highly variable chromosome numbers in
both breeds, which were generally in the range 42-58.
All cases evaluated exhibited an abundance of aberrant
bi-armed chromosomes. These data suggest that in addi-
tion to numerical changes there also are large numbers
of structural changes that merit further evaluation in a
subsequent study.
Of the 146 HS cases available to this study (68 BMD
and 45 FCR from the USA, and 33 BMD from France),
unfixed tumor biopsies were obtained for 125 (Addi-
tional file 2: Table S2). Tumor specimens from 104
cases (33 FCRs, 71 BMDs) yielded DNA of sufficient
quality to permit aCGH analysis, of which 86 (82.6%)
(30 FCRs, 56 BMDs) presented with detectable CNAs.
The remaining 18 cases (17.3%) (3 FCR and 15 BMD)
did not demonstrate any detectable CNAs at 1 Mb reso-
lution, presumably either due to an abundance of non-
malignant tissue in the biopsy received, or the presence
of a highly polyclonal cell population with few shared
aberrations. Since these 18 cases provided no evidence
for CNAs they were excluded from subsequent analyses.
Typically, aCGH profiles for individual canine HS
cases demonstrated numerous CNAs, both gains and
losses, throughout the genome (Figure 3a), which were
supported by FISH analysis of select regions (Figures 3b,
c and 3d). When considered as a single population of 86
aberrant cases, the genome wide aCGH profiles for
canine HS shared numerous CNAs (Figure 4). Thirty-
one regions of the canine genome presented with recur-
rent DNA copy number increases (present in ≥30% of
the combined cohort), comprising eight regions of gain
and 23 regions of loss. Of these 31 regions, six were
highly recurrent (present in ≥50% of the combined
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Figure 1 Distribution of the age of diagnosis of HS in US-
resident BMD (68 cases) and FCR (45). The mean age of HS
diagnosis is significantly different between BMD (7.7 yrs) and FCR
(8.6 yrs) (pval = 0.01, Mann-Whitney U test).
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Figure 2 Anatomical distribution of histiocytic tumors in FCR
and BMD. Anatomical location of HS is significantly different
between the two breeds (p value < 0.001, Fisher Exact test).
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Figure 3 Molecular cytogenetic evaluation of a canine histiocytic malignancy using aCGH and FISH. A. Example of whole genome aCGH
profile of a HS in a five year old female FCR. Log2 ratios representing thresholds of genomic gain and loss are indicated by horizontal bars
above (green line) and below (red line) the midline (orange line), which represents normal copy number. The chromosome copy number status
line for the tumor appears as an orange overlay of the center-line when there is a normal copy number, and as either green (gain) or red (loss)
in the regions where genomic imbalances were apparent, as determined by the aCGH Smooth algorithm [29]. The aCGH profile is annotated
with the clone address of nine BAC clones from the 1 Mb array that were used in subsequent FISH analysis of this case. Three of these nine
clones have been shown previously to contain the full coding sequence of a key cancer-associated gene (CDKN2A, RB1, PTEN) [26]. The color of
the text denotes the fluorochrome with which the BAC clone was labeled. B, C Targeted FISH analysis of tumor metaphase chromosome
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cohort), all of which were deletions; located on dog
chromosome 2 (Canis familiaris, CFA 2) (50% cases),
CFA 11 (62.8% of cases), CFA 16 (86% of cases), CFA
22 (64% of cases) and CFA 31 (61.6% of cases). Overall
the mean number and size of CNAs in both breeds was
highly comparable (Table 1), although the proportion of
cases that showed no detectable CNAs was 2.3 fold
greater in the BMD (21%) than in the FCR (9%). Figure
5 shows the size distribution of regions of CNA within
the FCR and BMD, indicating that in both breeds more
than 50% of the observed deletions were >30 Mb in
size, while half of the gains were <15 Mb.
Identification of recurrent population associated
aberrations
Segregation of aCGH data by breed revealed remarkable
genome-wide similarity in the gross distribution of geno-
mic gains and losses between BMD and FCR (Figure 6),
indicating that most of the CNAs identified were
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Figure 4 Whole genome CNA penetrance plot showing the percentage of all HS cases in the cohort (BMD+FCR; n = 86 cases) that
presented with detectable DNA copy number gain (green) and loss (red) along the length of each dog chromosome (CFA 1 to CFA
38), surveyed at 1 Mb intervals. The asterisks indicate those seven chromosomes (CFA 10, 15, 22, 25, 30, 35 and 36) that have regions of CNAs
differing significantly between BMD and FCR.
Table 1 Summary of the overall DNA copy number status
in the study population.
BMD FCR Mean (+/- st.dev)
mean number of CNAs 30.3 ± 17.8 32.2 ± 17.8 30.7 ± 17.6
mean number of losses 15.9 ± 9.3 18.1 ± 7.2 16.7 ± 8.6
mean number of gains 13.8 ± 10.3 14.1 ± 12.3 13.9 ± 10.9
ratio losses:gains 1.15:1 1.27:1 1.22:1
mean size of loss (Mb) 30.7 ± 21 35.7 ± 20.5 32.5 ± 21
mean size of gain (Mb) 23.3 ± 23.7 22.4 ± 20.5 23.1 ± 22.6
(CNAs = Copy Number Aberrations, BMD = Bernese Mountain Dog, FCR = Flat
Coated Retriever, Mb = Megabase).
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common to both breeds. To identify whether the geogra-
phical origin of a patient (USA or France) had any signifi-
cant effect on its genome wide CNA profile, principal
component analysis (PCA) was used to investigate poten-
tial population substructure within the BMD cohort.
Visual inspection of the scree plot of the first ten poten-
tial components indicated just a single significant compo-
nent (Figure 7a). Eigen values for the first three
components are represented in three-dimensional space
in Figure 7b, which demonstrates that there is no division
between BMD patients by geographical origin. Mann-
Whitney U tests showed no significant association
between the eigen values from the first five components
and the geographic origin of the patient (p > 0.05 for
each test). These results indicate there is no substantial
population substructure between American and French
BMDs. Based on these results the American and French
BMDs were evaluated as one single population in subse-
quent association analysis.
PCA was also used to assess evidence for global differ-
ences in the distribution of genome-wide DNA copy
number aberrations between the two breeds (Figure 8a).
These results indicate four significant components that
define the global data. The eigen values were generated
corresponding to the first four components and were
tested for association with breed using nonparametric
Mann-Whitney U tests (Table 2). The results of these
association tests indicate a statistically significant asso-
ciation between breed and the second principal compo-
nent (p < 0.0001). Figure 8b shows that there is a strong
division between the two breeds defined by the second
component, visually representing the association demon-
strated in Table 2. Tumor location was also tested for
association with the eigen values for the first four prin-
cipal components (Table 2), the results indicating a sig-
nificant association between tumor location and the
second principal component. Since there is a highly sig-
nificant association between breed and tumor location,
it is not possible to determine if it is the breed or the
tumor location that is driving the association and so this
must be considered when interpreting the results of
breed association with CNA.
Fisher’s exact tests of associations were performed for
each region of DNA copy number gain or loss and
breed, to identify specific regions of aberrations that
define this global difference (Table 3). The permutation
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distribution indicated that an uncorrected p-value < 0.01
was statistically significant at a family-wise error rate
(FWER) of 0.05. Copy number aberrations involving 13
regions on seven different chromosomes (CFA 10, 15,
22, 25, 30, 34, and 36) were significantly associated with
breed.
Evaluation of tumor suppressor gene deletions in canine
HS
A subset of recurrent CNAs identified in this study
involved regions of the genome that contain known can-
cer associated genes and were investigated further. Dele-
tion of CFA 11q16 at ~44 Mb, which includes the
tumor suppressor gene CDKN2A/B, was identified in
62.8% of HS cases (60.7% of BMD and 66.7% of FCR)
(Figure 6). This region was further evaluated by LOH
analysis of 26 BMD and 20 FCR cases, each of which
exhibited CFA 11q16 deletion in aCGH analysis, and
had high quality DNA available from both peripheral
blood and tumor specimens. Genotyping of seven
microsatellites surrounding the CDKN2A/B locus
demonstrated LOH of at least one microsatellite within
this region in all 46 cases, consistent with the loss of
CFA 11q16 identified by aCGH (data not shown). More-
over, LOH analysis of an additional 11 cases, in which
loss of this region of CFA 11 was not apparent from
aCGH analysis, revealed that six (54%) showed LOH of
at least one marker close to the CDKN2A/B locus (data
not shown). The common region deleted in both breeds
was centered on the CDKN2A/B locus. Two of the cases
used for this analysis showed log2 tumor DNA:reference
DNA ratios < -1.0 at the CDKN2A/B locus, highly sug-
gestive of an homozygous deletion. Subsequent FISH
analysis using a BAC clone containing the CDKN2A/B
locus confirmed homozygous deletion of this region in
these tumors (see Figure 3 for an example).
The most frequent DNA copy number aberration
observed by aCGH in the HS cohort was deletion of
CFA 16, with a 6 Mb segment of this chromosome
(extending from 47-53 Mb) deleted in 86% of all cases
(80.4% of BMD and 96.7% of FCR). These data were
Figure 7 Principal Component Analysis (PCA) to identify
potential population substructure between French and
American BMD cases of HS. A). Scree plots of the eigen values
first 10 components. B). Three dimensional plot of the first three
components. American BMD patients are indicated in red while
French BMD patients are indicated in blue.
Figure 8 Principal Component Analysis (PCA) to assess global
variation in aberration frequency between BMD and FCR. A)
Scree plots of the eigenvalues first 10 components. B) Three
dimensional plot of the first three components. BMD patients are
indicated in red and FCR patients are indicated in blue.
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supported by FISH analysis (see Figure 3 for an exam-
ple) and LOH analysis on a subset of 26 BMDs and 20
FCRs for which matched blood and tumor DNA sam-
ples were available (data not shown). The second most
frequently observed CNA in our cohort was deletion of
CFA 22q11 at ~60.5 Mb, which includes the tumor sup-
pressor gene RB1. DNA copy number loss of this region
was identified in 55.8% of all cases, with deletions twice
as common in the FCR (83.3% of FCRs and 41.1% of
BMDs). The TP53 tumor suppressor gene locus (CFA
5q21 at ~35.5 Mb) was gained in 26.7% of all cases,
with the frequency in the FCR (40%) being twice that of
the BMD (19.6%). Further, gain of this region was
almost three times more frequent than loss (26.7% gain
vs 9.3% loss) across all cases and also within both breeds
when considered separately (10.7% loss in BMDs, 6.6%
loss in FCRs). aCGH indicated that deletion of the full
length of CFA 26 was evident in approximately 10-20%
of cases. In both breeds, however, deletion of the distal
end of CFA 26, a region that contains PTEN, was
deleted in 40.7% of cases (42.9% of BMD, 36.7% of
FCR), representing the highest frequency of loss along
this chromosome. FISH analysis with BAC clones repre-
senting CDNK2A/B, RB1, TP53 and PTEN supported
the copy number status identified by aCGH in those
cases evaluated.
Discussion
We hypothesized that spontaneous canine HS exhibit
recurrent CNAs of genes involved in histiocytic canceri-
zation, and that identification of these CNAs may
advance our understanding of the molecular characteris-
tics of these cancers in both canine and human patients.
The pathophysiologies of several dog and human can-
cers share many similarities and our previous studies
have demonstrated that CNAs in a variety of human
cancers are evolutionarily conserved in the correspond-
ing canine cancer [40-42]. These findings support the
idea of a fundamental and evolutionarily conserved asso-
ciation between cytogenetic abnormalities and tumor
phenotype, indicating similar biological consequences in
both species [41]. In testing our hypothesis we recruited
client owned BMD and FCR patients, each with a con-
firmed diagnosis of HS, and performed genome-inte-
grated aCGH analysis of 104 cases to identify recurrent
CNAs at 1 Mb resolution. We also performed statistical
analysis of clinical and demographic data from our HS
cohort in order to expand knowledge of the epidemiolo-
gical basis of this disease in these breeds.
Disseminated canine HS was first described as malig-
nant histiocytosis in the BMD [19,20], and while this
condition has been documented in other breeds [17], it
appears that this clinical form continues to be reported
more frequently in the BMD than other breeds. Conver-
sely, Fidel et al. (2006) [25] described that the majority
of HS in the FCR were restricted to a joint and/or mus-
cle/skin, corresponding to a localized form of HS. Epide-
miological data from our cohort are consistent with
previous reports. Our data showed also that the anato-
mical location of the histiocytic tumors differed signifi-
cantly between the two breeds investigated: BMDs
present more frequently with tumors of internal organs
and also with a high frequency of dissemination, while
FCRs more often develop a localized tumor of the skin
or leg. To our knowledge this study represents the first
to provide statistical significance for these parameters.
The contrasting patterns of anatomical location of HS
in the BMD and FCR suggest that the genetic back-
grounds of these two breeds may play a key role in
Table 2 Test of association between the first eigenvalues for the first four principal components and breed (BMD/FCR)
or tumor location (internal/external)
Component P-value for association test with breed P-value for association test with tumor location
1 0.4174 0.08205431
2 <0.00001 7.12E-05
3 0.1291 0.06926817
4 0.2995 0.82846813
Table 3 Thirteen regions along seven dog chromosomes
showed significant differences between BMD and FCR
tumors.
CFA position (Mb) P-value
10 25-30 <0.0057
15 19-22 <0.0063
15 29-49 <0.0094
15 52-54 <0.0059
22 00-12 <0.0023
22 31-48 <0.0089
22 54-57 <0.0064
25 09-12 <0.0046
25 14-18 <0.0062
30 26-28 <0.0040
30 30-33 <0.0076
34 45-46 <0.0094
36 00-20 <0.0099
The megabase (Mb) position of these regions on different chromosomes (CFA)
is indicated. The uncorrected p-value is shown.
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determining risk, location and progression of this neo-
plasm, which could be assessed using genome wide
association analyses. Prior human and mouse studies
have identified specialized DC subtypes with heteroge-
neous functions [43] and so it is possible that the HS
diagnosed in FCR and BMD represent malignancies of
different DC subtypes, which might explain the different
behavior of these cancers in the two breeds.
Identification of breed-associated genomic copy number
aberrations
No statistical differences were found between CNAs
detected in HS of BMDs from two distinct geographic
areas (France/USA). These data suggest that it is reason-
able to sample BMDs from different geographic areas to
increase the number of cases available for subsequent
statistical analyses. This is not surprising considering
the BMD has its roots in Switzerland in the late 19th
century, was admitted to the AKC registry in 1937, and
experienced numerous international ‘line-exchanges’
over the ensuing 74 years. These data suggest a rela-
tively homogeneous international population, supporting
the conclusion of Quignon et al. [44] who proposed the
use of international BMD cohorts for genetic studies.
From a population genetics perspective, since the main
populations of BMD are located in the USA and Europe,
and there are no apparent differences in CNAs evident
at 1 Mb resolution between the two BMD populations,
we surmise that the genomic changes associated with
HS are common to all BMDs regardless of geographic
origin. This in turn may indicate that any risk factors
for the development and progression of HS are linked
tightly to the genetic makeup of the breed and indepen-
dent of geography. Advances in understanding of the
biological mechanism of HS in BMDs in the USA
should therefore apply also to BMDs in other countries,
extending the value of such studies.
Most of the CNAs identified in this study were com-
mon to both the BMD and the FCR, and so it is likely
that such aberrations may also be evident in other
breeds presenting with these malignancies. We identified
13 regions of the genome on seven chromosomes that
showed a significant association between DNA copy
number and breed of the patient (Table 1). Further,
PCA indicated a significant association between specific
CNAs and either breed (BMD/FCR) or anatomical loca-
tion(s) of the tumor(s). Since breed and tumor location
are so closely correlated, it is not possible from this
study to determine whether the association between
CNAs and breed was driven by breed itself or by the
anatomical location of the tumor in that breed. Aberra-
tions may be associated with location of affected organ/
tissue, and/or dissemination/metastatic nature of HS.
These aberrations could confer a proliferative advantage
to the tumor in one particular organ, or elevate the risk
of metastasis. An alternative hypothesis is that some of
these aberrations are linked specifically with the genetic
background of each breed. Since it has been shown pre-
viously that individual genetic backgrounds, as defined
by breed in dogs, influence tumor karyotypes [40,45],
we could hypothesize that some pathways are inacti-
vated by germline mutations in one breed, creating a
genetic risk for HS, but are inactivated by somatic modi-
fications (genomic loss, mutation) in the second breed.
Evaluation of HS in additional breeds that also present
with a disseminated form of the disease, such as the
Rottweiler, will aid in determining whether the apparent
separation between BMD and FCR is driven by breed or
by anatomical features of the cancer [9].
Identification of highly recurrent CNAs shared by the FCR
and the BMD - candidate regions for human HS
Despite the high level of genome reorganization evident
in canine HS and the varying anatomical location of the
tumors between breeds, we identified numerous CNAs
within our sample population shared between the both
breeds. Several of these were classified as recurrent
(≥30% frequency) or highly recurrent (≥50% frequency).
Among the most highly recurrent CNAs detected were
loss of regions of CFA 2, CFA 11, CFA 16, CFA 22 and
CFA 31, all of which were highly frequent (50-86%) in
both breeds. The presence of highly recurrent abnormal-
ities common to both breeds, along with their presence
in both the localized and disseminated forms of HS, is
suggestive of an association more with the cancer phe-
notype than with breed. These regions likely contain
genes that may play a key role in malignant transforma-
tion of histiocytes, independent of anatomical location.
This is especially so for the most frequent CNA, dele-
tion of CFA 16, an aberration that was detected in 86%
of HS cases (80.4% of BMD, 96.7% of FCR).
At first glance many of the recurrent aberrations iden-
tified in this study involved large contiguous tracts of
the canine genome (Figures 4 and 5), and so identifica-
tion of candidate genes is challenging. Closer considera-
tion of subchromosomal differences in aberration
frequency may however be used to determine minimal
regions of interest. For example, Figures 4 and 5 indi-
cate that while the full length of CFA 16 is deleted in at
least 50% of all HS cases (both FCR and BMD), there
are regional differences in the frequency of deletion
along the length of the chromosome. The highest fre-
quency of recurrent deletion (86%) along CFA 16
involved a 6 Mb region (47-53 Mb) towards the telo-
meric end of the chromosome. There are several anno-
tated candidate genes within this region of the canine
genome http://genome.ucsc.edu/cgi-bin/hgGateway?
db=canFam2 that are known either to be involved in
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regulation of apoptosis, or which are suspected to be
tumor suppressor genes; including CDKN2A interacting
protein (CDKN2AIP), FAT tumor suppressor homolog1
(FAT1), Tumor suppressor candidate 3 (TUSC3), Mito-
chondrial Tumor Suppressor gene 1 (MTUS1) and peri-
centriolar material-1 (PCM1). Of comparative
significance specific to HS, CDKN2AIP is known to
interact with CDKN2A/p14ARF, TP53/p53 and MDM2,
all of which have been shown to be involved in human
histiocytic disorders [4,8,9,11-14,46] and so this merits
further investigation in future studies.
Similarly, a neighboring 2.4 Mb region of CFA 16 (41.8
Mb-44.2 Mb) was deleted in 84.9% of HS cases. Of possi-
ble comparative significance, this region of CFA 16 is in
part orthologous to human chromosome (HSA) 8p22-
p21.3, a region that is frequently deleted in numerous
tumors, including multiple myeloma, prostate cancer,
hepatocellular carcinoma and neck squamous cell carci-
noma [47-50]. These data indicate that in both human
and canine cancers, this region exhibits a strikingly high
and comparable level of CNA. Further evaluation of both
human and canine patients will be required to determine
whether this shared deletion contains genes and regula-
tory elements associated with HS, or if its presence is
merely a generalized passenger aberration.
aCGH profiling of canine HS suggests that disruption of
the p53 and Rb pathways is a common event
Segments of CFA 11 (q22), 22 (q11) and 26 (q25) all
showed a high incidence of copy number loss in canine
HS. Each of these three regions contain key cancer asso-
ciated genes involved in the p53 and Rb pathways:
CDKN2A/B (CFA 11q22), RB1 (CFA 22q11) and PTEN
(CFA 26q25). CDKN2 encodes three distinct tumor sup-
pressor genes (ARF, p15INK4b p16INK4a) that code for pro-
teins regulating cell cycle progression via the Rb and p53
pathways. While p15INK4b and p16INK4a regulate the Rb-
pathway, ARF inactivates MDM2 protein and so regu-
lates p53 [51,52]. The human region orthologous to CFA
11q22 is HSA 9p21, which is among the most frequent
sites of DNA copy number loss in human cancers [53].
Genes within this region, especially p16INK4a, have also
been shown to be inactivated in several dog cancers
including lymphoma, melanoma, hemangiosarcoma and
osteosarcoma [42,54-59]. Since direct inactivation of
p16INK4a by point mutation, deletion or promoter methy-
lation is evident in approximately one third of human
hematopoietic tumors [53,60], it is not surprising to find
this locus is involved in human histiocytic disorders. Sig-
nificantly, monosomy of HSA 9, including the CDKN2
locus, has been observed in different human dendritic
proliferations including plasmacytoid DC sarcoma [8]
and follicular DC sarcoma [9]. Moreover deletion of HSA
9p has been reported as the second most frequently
observed aberration in Langerhans cell histiocytosis
(LCH) of the lung [10]. In mice, loss of INK4a allows
macrophages to bypass senescence [61] and Pten and
Ink4a/Arf have a cooperative role in restricting macro-
phage growth. The same is true in human HS where
inactivation of PTEN and INK4a/ARF tumor suppressors
are critical steps in the pathogenesis of this cancer [4,11].
It is therefore of interest that in this study >50% of HS
cases presented with a deletion of the CDKN2 locus.
Other mechanisms, such as DNA sequence mutations or
methylation, may also inactivate these tumor suppressor
genes. In future studies it will be important to investigate
whether HS cases presenting with no apparent deletion
of CDKN2 have an increased rate of DNA sequence
mutation of this locus, resulting in aberrant expression
for reasons other than gene dosage.
Also belonging to these key pathways is the gene Retino-
blastoma 1 (RB1), which is disrupted in a variety of
human solid tumors including pituitary adenomas, eso-
phageal carcinoma, gliomas and ovarian cancer [62]. Dele-
tion of HSA 13q14, containing RB1, is also a common
event in a wide variety of acute/chronic myeloid disorders
as well as in human dendritic sarcomas (plasmacytoid DC
and follicular DC sarcomas) [8,63]. In our study, loss of
the RB1 locus on CFA 22 was highly recurrent across the
cohort (55.8% of HS cases) although it was detected twice
as frequently in HS tumors of FCRs than of BMDs (83.3%
of FCR cases vs 41.1% of BMD cases).
Deletion of HSA 17p, containing TP53, has been
described in human LCH [10,12], while other studies
reported an elevated expression of p53 in this disease
[13,14]. In the present study, 36% of canine HS cases
demonstrated CNA of TP53, representing copy number
loss in 9.3% cases and gain in 26.7% of cases. Further
studies are needed to assess if gene dosage of TP53, as
well as other mechanisms, result in altered expression of
p53 that may be correlated with elevated expression of
this protein in Langerhans cell proliferation.
Deletion of CFA26 was present in approximately 20%
of canine HS cases, but the telomeric end of this chro-
mosome, a region encoding the PTEN locus, was deleted
in ~41% of cases, regardless of breed. PTEN plays a sig-
nificant role in inducing cycle arrest and programming
apoptosis. It is an antagonist of the PI3K/AKT pathway,
and in turn regulates the Rb pathway [64]. It also con-
trols p53 protein levels and transcriptional activity
through both phosphatase-dependent and independent
mechanisms [65]. PTEN has been shown to be deleted
or mutated in a wide range of human tumors [64] and
also in several canine tumors [58,66]. While PTEN influ-
ences p53 transcriptional activity and p53 stability [65],
no association was found in our data between gain/loss
of TP53 and PTEN loss (Fisher’s Exact test, data not
shown).
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Copy number aberrations common to both breeds,
combined with their likely consequential impact on the
same pathways in human and canine HS, support the
relevance of the dog as a model of HS. In addition to
the genes discussed above we suspect that other tumor
suppressors on CFA 2, CFA 16 and CFA 31 (deleted in
50%, 86% and 61.6% of HS tumors, respectively) also
may play an important role in histiocytic cancerization.
Their identity likely will become apparent with increased
resolution and functional analysis of genes within these
regions.
Conclusions
This study demonstrates that histiocytic sarcomas of
two dog breeds with distinct genetic backgrounds (BMD
and FCR), but sharing a high incidence of the disease,
present with highly aberrant genome-wide DNA copy
number profiles. The presence of numerous highly
recurrent CNAs shared by both BMD and FCR tumors
suggests that these are associated more with the cancer
phenotype than breed. The small number of breed asso-
ciated CNAs identified may contribute to the major dif-
ferences in the varying tumor location evident in these
two breeds. The most highly recurrent aberrations
revealed in this study are evolutionarily conserved with
those reported in human histiocytic proliferations, sug-
gesting that human and dog HS share a conserved
pathogenesis. The breed associated clinical features and
chromosomal aberrations of canine HS offer a valuable
spontaneous model for the human counterpart, aiding
elucidation of the pathophysiological and genetic
mechanisms associated with histiocytic malignancies and
providing new opportunities for developing effective
therapeutic modalities for both species.
Additional material
Additional file 1: Table S1. List of microsatellite markers used for
LOH study. The position of each sequence is shown as the base pair
location in the canine genome assembly, canFam2. Forward primers of
CFA 11 markers had an M13-tail and were used with an M13 primer
fluorescently tagged at the 5’ end either with PET, VIC, FAM or NED to
facilitate multiplexing.
Additional file 2: Table S2. Signalment and clinical data for all 125
canine histiocytic sarcoma cases for which unfixed tumor biopsies
were available. Unshaded cases indicate 86 cases used for aCGH data
analysis. Cases that did not yield sufficient quality DNA and those that
did not contain evident CNAs are highlighted in grey.
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